A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(2 sites) United States
UCLA Westwood, Los Angeles, California UCSF Community and Clinical Research Center, San Francisco, California
Key details Phase
Early testing / Safety & dosing
Collaborators
University of California, San Francisco, University of California, Davis
Enrollment target
~80 participants
Primary completion
December 2027
Age range
40 Years – 64 Years
Last updated October 2025